Next Article in Journal
Dermaseptin-PH: A Novel Peptide with Antimicrobial and Anticancer Activities from the Skin Secretion of the South American Orange-Legged Leaf Frog, Pithecopus (Phyllomedusa) hypochondrialis
Previous Article in Journal
Silver Nanoparticles Stabilised by Cationic Gemini Surfactants with Variable Spacer Length
Previous Article in Special Issue
Protective Effect of Prunus Cerasus (Sour Cherry) Seed Extract on the Recovery of Ischemia/Reperfusion-Induced Retinal Damage in Zucker Diabetic Fatty Rat
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Molecules 2017, 22(10), 1795; doi:10.3390/molecules22101795

Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases

1
Department of Biomedical Sciences and Institute for Medical Science, Chonbuk National University Medical School, Jeonju, Chonbuk 54907, Korea
2
Department of Microbiology, Seonam University Medical School, Namwon, Chonbuk 55321, Korea
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 31 August 2017 / Revised: 17 October 2017 / Accepted: 20 October 2017 / Published: 24 October 2017
(This article belongs to the Special Issue Bioactive Compounds for Metabolic Syndrome and Type 2 Diabetes)
View Full-Text   |   Download PDF [613 KB, uploaded 25 October 2017]   |  

Abstract

Metabolic syndrome (MetS) is a cluster of metabolic risk factors associated with central obesity, hyperglycemia, insulin resistance, dyslipidemia and high blood pressure. In recent decades, because of the remarkable increase in both prevalence and severity, MetS and its related diseases such as cardiovascular diseases (CVDs), obesity, hypertension and diabetes have become the main global burden and challenge in strategic management involving prevention and treatment. However, currently, the preventions and treatments based on pharmaceutical interventions do not provide a solution for MetS and its related diseases. Recently, gut microbiota showed clear evidence of preventing and/or treating MetS, shedding light on treating MetS and its related diseases through a completely different approach. In this review, we will interpret the effects of current pharmaceutical drugs used in preventing and treating MetS and its related diseases to understand remaining issues of those interventions. We will explore the possibility of developing gut microbiota as pharmabiotics in a completely new medication option for treating MetS and its related diseases. View Full-Text
Keywords: pharmabiotics; metabolic syndrome; obesity; diabetes; dyslipidemia; hypertension; cardiovascular diseases; gut microbiota pharmabiotics; metabolic syndrome; obesity; diabetes; dyslipidemia; hypertension; cardiovascular diseases; gut microbiota
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nguyen, T.T.B.; Jin, Y.Y.; Chung, H.-J.; Hong, S.-T. Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases. Molecules 2017, 22, 1795.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top